Teva On Track To Hit Targets With Truxima
Targeting New Patients With US Rituximab Biosimilar
Teva says it is on track to achieve both its sales targets and its restructuring goals as it prepares to enjoy the benefits of being first to market with a rituximab biosimilar in the US.
You may also be interested in...
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
By getting out of unprofitable product lines, Teva showed the way for industry to stabilize pricing and value in the US retail generics sector, the Israeli group’s president and CEO Kåre Schultz told investors at a J.P. Morgan conference.
Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.